|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in participants with clinical symptoms of COVID-19 that have begun within the past 48 hours prior to testing.
Description: Rate of decline in viral load over the 10 days after randomization between participants treated with RBV and NTZ for COVID-19 and placeboMeasure: Rate of decline in viral load Time: 10 days
Description: Time to resolution of viral load, defined by reduction of virus below LLOQ and maintaining it for 2 days.Measure: Time to resolution of viral load Time: 28 days
Description: Comparison of proportion of subjects who are asymptomatic and symptomatic at day 10Measure: Comparison of proportion of subjects who are asymptomatic and symptomatic Time: 10 days
Description: To assess the rate of decline in viral load over days 3 and 6 after randomizationMeasure: Rate of decline in viral load Time: Days 3 and 6
Description: Assess change in modified National Early Warning System-2 items on a scale of 0 to 20. HIgher scores meaning greater clinical risk.Measure: Change in modified NEWS-2 Time: 28 days
Description: Proportion of subjects with treatment emergent adverse events leading to study drug discontinuationMeasure: Proportion of subjects with treatment emergent adverse events Time: 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports